The NEAT Predictive Model for Survival in Patients with Advanced Cancer

다국어 초록 (Multilingual Abstract)

Purpose We previously developed a model to more accurately predict life expectancy for stage IV cancer patients referred to radiation oncology. The goals of this study are to validate this model and to compare competing published models.
Materials and Methods From May 2012 to March 2015, 280 consecutive patients with stage IV cancer were prospectively evaluated by a single radiation oncologist. Patients were separated into training, validation and combined sets. The NEAT model evaluated number of active tumors (“N”), Eastern Cooperative Oncology Group performance status (“E”), albumin (“A”) and primary tumor site (“T”). The Odette Cancer Center model validated performance status, bone only metastases and primary tumor site. The Harvard TEACHH model investigated primary tumor type, performance status, age, prior chemotherapy courses, liver metastases, and hospitalization within 3 months. Cox multivariable analyses and logistical regression were utilized to compare model performance.
Results Number of active tumors, performance status, albumin, primary tumor site, prior hospitalization within the last 3 months, and liver metastases predicted overall survival on uinvariate and multivariable analysis (p < 0.05 for all). The NEAT model separated patients into four prognostic groups with median survivals of 24.9, 14.8, 4.0, and 1.2 months, respectively (p < 0.001). The NEAT model had a C-index of 0.76 with a Nagelkerke’s R2 of 0.54 suggesting good discrimination, calibration and total performance compared to competing prognostic models.
Conclusion The NEAT model warrants further investigation as a clinically useful approach to predict survival in patients with stage IV cancer.

참고문헌 (Reference)

1 Chow E, "Validation of a predictive model for survival in patients with advanced cancer: secondary analysis of RTOG 9714" 2 : 181-190, 2011

2 백선경, "The Association between End-of-Life Care and the Time Interval between Provision of a Do-Not-Resuscitate Consent and Death in Cancer Patients in Korea" 대한암학회 49 (49): 502-508, 2017

3 Salama JK, "Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease" 118 : 2962-2970, 2012

4 Yourman LC, "Prognostic indices for older adults: a systematic review" 307 : 182-192, 2012

5 Rades D, "Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression" 24 : 3388-3393, 2006

6 Chow E, "Predictive model for survival in patients with advanced cancer" 26 : 5863-5869, 2008

7 Krishnan MS, "Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model" 120 : 134-141, 2014

8 Kao J, "Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response" 115 : 3571-3580, 2009

9 Gripp S, "Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth?" 116 : 3251-3256, 2010

10 Jones JA, "Palliative radiotherapy at the end of life: a critical review" 64 : 296-310, 2014

11 Anderson F, "Palliative performance scale (PPS): a new tool" 12 : 5-11, 1996

12 Milano MT, "Oligometastases treated with stereotactic body radiotherapy: long-term followup of prospective study" 83 : 878-886, 2012

13 Chen HM, "Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy" 21 : 4073-4085, 2015

14 Harrell FE Jr, "Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors" 15 : 361-387, 1996

15 Gomez DR, "Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study" 17 : 1672-1682, 2016

16 Sperduto PW, "Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-mol-GPA)" 3 : 827-831, 2017

17 Morden NE, "End-of-life care for medicare beneficiaries with cancer is highly intensive overall and varies widely" 31 : 786-796, 2012

18 Mack JW, "End-of-life care discussions among patients with advanced cancer: a cohort study" 156 : 204-210, 2012

19 Sperduto PW, "Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients" 77 : 655-661, 2010

20 Mulvenna P, "Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial" 388 : 2004-2014, 2016

21 Feliu J, "Development and validation of a prognostic nomogram for terminally ill cancer patients" 103 : 1613-1620, 2011

22 Kao J, "Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial" 9 : 145-153, 2014

23 Lamont EB, "Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to"" 290 : 98-104, 2003

24 Newson RB, "Comparing the predictive powers of survival models using Harrell's C or Somers' D" 10 : 339-358, 2010

25 Koshy M, "Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer" 5 : 374-382, 2015

26 Kao J, "Clinical predictors of survival for patients with stage IV cancer referred to radiation oncology" 10 : e0124329-, 2015

27 Inui A, "Cancer anorexia-cachexia syndrome: current issues in research and management" 52 : 72-91, 2002

28 Hartsell WF, "Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14" 11 : 723-728, 2008

29 Steyerberg EW, "Assessing the performance of prediction models: a framework for traditional and novel measures" 21 : 128-138, 2010

30 Chow E, "Accuracy of survival prediction by palliative radiation oncologists" 61 : 870-873, 2005